|
02 May 2023 |
Elicera Therapeutics receives conditional approval from the Medical Products Agency on its CAR T-cell Clinical Trial Application to test ELC-301 (CARMA-study)
|
|
02 May 2023 |
Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration
|
|
02 May 2023 |
Atsena Therapeutics Receives FDA Clearance of IND Application for ATSN-201, an Investigational Gene Therapy for the Treatment of X-linked Retinoschisis
|
|
02 May 2023 |
Bristol Myers Squibb’s TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma Meet Primary Endpoint of Overall Response Rate
|
|
02 May 2023 |
CG Oncology Announces New Phase 2 Data with Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA® (pembrolizumab) in BCG-Unresponsive NMIBC
|
|
02 May 2023 |
Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer
|
|
02 May 2023 |
SIRPant Immunotherapeutics Announces FDA Clearance of IND Application for SIRPant-M™ Autologous SIRPαlow Activated Macrophage Immunotherapy
|
|
02 May 2023 |
Cellenkos Announces First Patient Dosed with CK0803 Cell Therapy for Treatment of Amyotrophic Lateral Sclerosis
|
|
28 Apr 2023 |
Celularity Announces Clinical Data on Human Placental-Derived Unmodified Allogeneic Natural Killer Cell Therapy Candidate Cynk-001 in Adult Patients With Relapsed Refractory and Measurable Residual Disease-Positive Acute Myeloid Leukemia
|
|
28 Apr 2023 |
Cartherics grants Shunxi Licence for CAR-T Cell Therapy for Ovarian Cancer in Greater China
|
|
27 Apr 2023 |
4DMT Presents Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ARVO 2023
|
|
27 Apr 2023 |
Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWSTTM (fecal microbiota spores, live-brpk) for Prevention of Recurrence of C. difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI
|
|
27 Apr 2023 |
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
|
|
26 Apr 2023 |
AlloVir Announces Positive Results Including Long-Term Mortality Data in Phase 2 Posoleucel Multi-Virus Prevention Study in Oral Presentation at EBMT 2023
|
|
26 Apr 2023 |
Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom
|
|
26 Apr 2023 |
FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
|
|
25 Apr 2023 |
Eyevensys Announces Positive Preclinical Data Demonstrating Superiority of EYS809 over Aflibercept for Wet Age-Related Macular Degeneration (AMD) at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
|
|
25 Apr 2023 |
IN8bio Presents Positive, New INB-100 Data Showing Long-term Complete Remissions and Elevated Gamma-Delta T Cells in 100% of Evaluable Treated Leukemia Patients at EBMT 2023
|
|
25 Apr 2023 |
NEURO-TTRansform Phase III results presented at AAN showed eplontersen demonstrated consistent and sustained improvement in all measures of disease and quality of life through 66 weeks
|
|
25 Apr 2023 |
bluebird bio Submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events
|
|
24 Apr 2023 |
MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease
|
|
21 Apr 2023 |
Locanabio Announces First Presentation of Data from its Next Generation Vectorized snRNA Exon-Skipping Platform Highlighting its Investigational LBIO-115 Program for the Treatment of Duchenne Muscular Dystrophy (DMD)
|
|
21 Apr 2023 |
CARsgen's CAR T-cell Candidate CT041 Achieves IND Clearance from the NMPA for the Postoperative Adjuvant Therapy of Pancreatic Cancer
|
|
20 Apr 2023 |
Nutcracker Therapeutics Demonstrates Immunotherapeutic Potency of Lead mRNA Candidate at the 2023 AACR Annual Meeting
|
|
20 Apr 2023 |
Myrtelle Announces Positive 6-month Post-Treatment Data in Patients in Its First-in-Human Clinical Study of rAAV-Olig001-ASPA Gene Therapy in Canavan Disease
|
